Kari L. Olson

2.1k total citations
63 papers, 1.7k citations indexed

About

Kari L. Olson is a scholar working on Economics and Econometrics, Geriatrics and Gerontology and Surgery. According to data from OpenAlex, Kari L. Olson has authored 63 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Economics and Econometrics, 24 papers in Geriatrics and Gerontology and 23 papers in Surgery. Recurrent topics in Kari L. Olson's work include Health Systems, Economic Evaluations, Quality of Life (26 papers), Pharmaceutical Practices and Patient Outcomes (23 papers) and Lipoproteins and Cardiovascular Health (19 papers). Kari L. Olson is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (26 papers), Pharmaceutical Practices and Patient Outcomes (23 papers) and Lipoproteins and Cardiovascular Health (19 papers). Kari L. Olson collaborates with scholars based in United States, Canada and Poland. Kari L. Olson's co-authors include David J. Magid, P. Michael Ho, John S. Rumsfeld, Susan Shetterly, Frederick A. Masoudi, Pamela N. Peterson, Thomas M. Maddox, John A. Merenich, Sarah J. Billups and Thomas Delate and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and The American Journal of Medicine.

In The Last Decade

Kari L. Olson

60 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kari L. Olson United States 21 587 575 508 499 371 63 1.7k
Lyne Lalonde Canada 27 580 1.0× 675 1.2× 498 1.0× 566 1.1× 233 0.6× 69 2.0k
Julie C. Lauffenburger United States 21 578 1.0× 317 0.6× 400 0.8× 452 0.9× 143 0.4× 86 1.8k
Daniel R. Touchette United States 24 332 0.6× 785 1.4× 422 0.8× 361 0.7× 143 0.4× 94 1.8k
Mary G. Amato United States 23 424 0.7× 797 1.4× 283 0.6× 275 0.6× 459 1.2× 57 2.0k
Sarah J. Billups United States 18 249 0.4× 639 1.1× 335 0.7× 340 0.7× 105 0.3× 63 1.1k
Valérie Santschi Switzerland 18 524 0.9× 598 1.0× 266 0.5× 373 0.7× 69 0.2× 47 1.3k
Simon Tang United States 17 426 0.7× 271 0.5× 353 0.7× 373 0.7× 196 0.5× 29 1.0k
Alessandro Filippi Italy 18 1.1k 1.9× 244 0.4× 290 0.6× 424 0.8× 207 0.6× 63 1.6k
E. Márquez Contreras Spain 19 648 1.1× 297 0.5× 160 0.3× 483 1.0× 158 0.4× 64 1.1k
Jeppe Nørgaard Rasmussen Denmark 21 1.6k 2.7× 372 0.6× 519 1.0× 619 1.2× 617 1.7× 27 3.3k

Countries citing papers authored by Kari L. Olson

Since Specialization
Citations

This map shows the geographic impact of Kari L. Olson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kari L. Olson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kari L. Olson more than expected).

Fields of papers citing papers by Kari L. Olson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kari L. Olson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kari L. Olson. The network helps show where Kari L. Olson may publish in the future.

Co-authorship network of co-authors of Kari L. Olson

This figure shows the co-authorship network connecting the top 25 collaborators of Kari L. Olson. A scholar is included among the top collaborators of Kari L. Olson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kari L. Olson. Kari L. Olson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Steiner, John F., et al.. (2023). Hypertension care during the COVID‐19 pandemic in an integrated health care system. Journal of Clinical Hypertension. 25(4). 315–325. 11 indexed citations
2.
Kono, Scott A., et al.. (2021). Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System. BioDrugs. 36(1). 1–11. 7 indexed citations
3.
Delate, Thomas, et al.. (2021). Clinical outcomes of dabigatran use in patients with non-valvular atrial fibrillation and weight >120 kg. Thrombosis Research. 208. 176–180. 8 indexed citations
4.
An, Jaejin, Catherine G. Derington, Tiffany Luong, et al.. (2020). Fixed-Dose Combination Medications for Treating Hypertension: A Review of Effectiveness, Safety, and Challenges. Current Hypertension Reports. 22(11). 95–95. 16 indexed citations
5.
Kurz, Deanna, et al.. (2019). Value of Pharmacy Students Performing Population Management Activity Interventions as an Advanced Pharmacy Practice Experience. American Journal of Pharmaceutical Education. 83(5). 6759–6759. 8 indexed citations
6.
King, Jordan B., et al.. (2018). Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service. Journal of clinical lipidology. 12(4). 999–1007. 5 indexed citations
7.
Olson, Kari L., et al.. (2013). Interventions aimed at improving performance on medication adherence metrics. International Journal of Clinical Pharmacy. 36(1). 20–25. 12 indexed citations
8.
Delate, Thomas, et al.. (2012). Out-of-Plan Pharmacy Use by Members of a Managed Care Organization. The Permanente Journal. 16(2). 15–21. 10 indexed citations
9.
Olson, Kari L., et al.. (2010). The Risk for Significant Creatine Kinase Elevation with Statins. American Journal of Cardiovascular Drugs. 10(3). 187–192. 12 indexed citations
10.
Olson, Kari L., et al.. (2010). An assessment of cholesterol goal attainment in patients with chronic kidney disease. Journal of clinical lipidology. 4(4). 298–304. 11 indexed citations
11.
Delate, Thomas, et al.. (2010). Reduced Health Care Expenditures After Enrollment in a Collaborative Cardiac Care Service. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(11). 1127–1135. 11 indexed citations
12.
Smith, Judith A., Kari L. Olson, & Kevin M. Sowinski. (2009). Pharmacy Practice Research Careers. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 29(8). 1007–1011. 11 indexed citations
13.
Delate, Thomas, et al.. (2008). Relationship between Haemoglobin A1C Values and Recurrent Cardiac Events. Clinical Drug Investigation. 28(8). 501–507. 11 indexed citations
14.
Denus, Simon de, et al.. (2008). Key Articles and Guidelines in the Management of Hypertension: 2008 Update. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 28(8). 1041–1058. 9 indexed citations
15.
Merenich, John A., et al.. (2007). Mortality Reduction Benefits of a Comprehensive Cardiac Care Program for Patients with Occlusive Coronary Artery Disease. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 27(10). 1370–1378. 35 indexed citations
16.
17.
Olson, Kari L., et al.. (2005). Assessment of Patient Satisfaction With Telephone and Mail Interventions Provided by a Clinical Pharmacy Cardiac Risk Reduction Service. Journal of Managed Care Pharmacy. 11(5). 403–409. 26 indexed citations
18.
Billups, Sarah J., et al.. (2005). Clinical and Economic Outcomes of Conversion of Simvastatin to Lovastatin in a Group-Model Health Maintenance Organization. Journal of Managed Care Pharmacy. 11(8). 681–686. 19 indexed citations
19.
20.
Olson, Kari L., Tammy J. Bungard, & Ross T. Tsuyuki. (2001). Cholesterol Risk Management: A Systematic Examination of the Gap from Evidence to Practice. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 21(7). 807–817. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lyne Lalonde Breakdown of academic impact, for papers by Julie C. Lauffenburger Breakdown of academic impact, for papers by Daniel R. Touchette Breakdown of academic impact, for papers by Mary G. Amato Breakdown of academic impact, for papers by Sarah J. Billups Breakdown of academic impact, for papers by Valérie Santschi Breakdown of academic impact, for papers by Simon Tang Breakdown of academic impact, for papers by Alessandro Filippi Breakdown of academic impact, for papers by E. Márquez Contreras Breakdown of academic impact, for papers by Jeppe Nørgaard Rasmussen
Rankless by CCL
2026